Phase 2 N=20 Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=135 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
Pemphigus Vulgaris
Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…
Phase 2 N=27 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Pemphigus Vulgaris
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 74.1; 86.7; 11.1; 0 percentage of participants
Phase 3 N=94 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
Pemphigus Vulgaris (PV)
Primary: Percentage of Patients Achieving Responder Status at Week 52 — 63.9; 69.0 Percentage of Participants — p=0.6558
Phase 2 N=23 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants
Phase 3 N=222 A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
Pemphigus Vulgaris · Pemphigus Foliaceus
Primary: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy — 44; 20 Participants
Phase 3 N=106 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Percent of Participants Achieving Sustained Remission at Week 36 — 4.0; 18.2 Estimated Percentage of Participants — p=0.0250
Phase 2 N=8 Rituximab in the Treatment of Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Primary Safety Endpoint — 0; 0; 1 participants
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Phase 2 N=11 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Pemphigoid, Bullous
Primary: Number of Participants With Anti-Drug Antibodies — 0 Participants
Phase 4 N=2 Efficacy and Safety of Omalizumab in Bullous Pemphigoid
Bullous Pemphigoid
Primary: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters. — 6 weeks
Phase 2 N=4 Ixekizumab in the Treatment of Bullous Pemphigoid
Bullous Pemphigoid · Pemphigoid
Primary: Cessation of Blister Formation — NA days
N/A N=2 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Phase 3 N=98 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Number of Participants With CRoff at Week 36 — 8; 2 Participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=4 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Pyoderma Gangrenosum
Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1
Phase 3 N=159 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001
Phase 2 N=123 A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Generalized Pustular Psoriasis
Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002
Phase 2 N=35 A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24
Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Palmoplantar Pustulosis
Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001
Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
Phase 1 N=7 Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
Psoriasis
Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants
Phase 1 N=31 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
Phase 2 N=14 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Epidermolysis Bullosa · Pruritus
Primary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI